iCellate welcomes Per Öhrn as new Director of Sales
Stockholm, Sweden – February 12, 2024 – iCellate strengthen the commercial team by adding Per Öhrn as Director of Sales. Per brings a wealth of experience from various sales roles in Sweden and Europe.
iCellate is delighted to announce that Per Öhrn has joined iCellate as our new Director of Sales, effective January 8, 2024. Per brings with him a wealth of experience and expertise in the MedTech and Pharma industry, along with a proven track record of driving sales and fostering growth in the Nordic region.
With over 25 years of experience, Per has held significant leadership roles, including Head of Global Sales and Marketing at Hiloprobe, where he played a pivotal role in expanding the company's presence across Europe. His strategic vision and hands-on approach have been instrumental in achieving remarkable success, evident from his tenure at Cyclomedica Nordic AB, where he doubled sales within a short period.
Per's extensive background also includes serving as Business Unit Manager at prestigious organizations like Fresenius-Kabi Sweden and Sorin Group Scandinavia/LivaNova, where he managed large teams and demonstrated exceptional leadership skills.
His relentless dedication and commitment to excellence align perfectly with iCellate's mission and values. As Director of Sales, Per will lead our sales efforts, driving growth, and establishing strong partnerships to further enhance our market presence.
Per will primarily be working with establishing relationships with Swedish and Nordic oncologists in pancreatic and prostate cancer, as well as fertilize our existing collaborations and building new ones with pharma companies.
About iCellate:
iCellate is a Swedish life science company founded in 2011 with its laboratory and office located in Stockholm. iCellate develops cancer diagnostic services across the cancer lifecycle, from hereditary cancer risk (GeneMate®) to early detection, treatment prediction and treatment monitoring (CellMate®).
The technologies are based on research from the Karolinska Institute in collaboration with the Karolinska University Hospital and the Royal Institute of Technology in Stockholm.
iCellate is accredited by Swedac as a medical laboratory according to ISO 15189
Read more at icellate.com.
